Biologic Therapy(TNF-α Antagonists)-Induced Psoriasis
Authors:
- Raquel CuchacovichRCRaquel Cuchacovich
- Carmen G. EspinozaCECarmen G. Espinoza
- Zia VirkZVZia Virk
- Luis R. EspinozaLELuis R. Espinoza
- 1 December 2008
- journal article
- case report
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 14 (6) , 353-356
Abstract
We report 3 patients with psoriatic arthritis and 2 with rheumatoid arthritis who developed worsening, and/or de novo psoriasis, and/or psoriasiform rash, while on tumor necrosis factor antagonist therapy. All 5 patients initially presented with active skin, and/or joint inflammatory involvement, and exhibited significant clinical response to tumor necrosis factor antagonist therapy. Within approximately 6 months, however, psoriatic and/or psoriasiform rash developed de novo in 2 rheumatoid arthritis patient and exacerbated in the other 3 patients. Biopsy findings revealed histologic and immunohistochemical changes indistinguishable from psoriasis.Psoriatic rash improved after discontinuation of biologic therapy and/or initiation of a short course of oral prednisone. One patient with psoriatic arthritis was rechallenged with infliximab due to exacerbation of both psoriasis and psoriatic arthritis, and this was followed by prompt improvement of both conditions. At 6 months follow-up, this patient remains under excellent control. To date, there have been over 50 cases of this type of dermatologic complication described. Interferon alpha seems to play an important role in the pathogenesis of this complication. This type of complication has been described with all 3 available tumor necrosis factor inhibitors, and most patients improve after discontinuation of biologic therapy.Keywords
This publication has 22 references indexed in Scilit:
- Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesJournal of Experimental Medicine, 2007
- Psoriatic arthritis: Current concepts on pathogenesis‐oriented therapeutic optionsArthritis & Rheumatism, 2007
- A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agentsAnnals of the Rheumatic Diseases, 2006
- Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation existsAnnals of the Rheumatic Diseases, 2006
- Anti-Tumor Necrosis Factor Alpha-Induced Psoriasiform Eruptions: Three Further Cases and Current OverviewDermatology, 2006
- Anti‐TNF‐α‐induced psoriasis: Case report of an unusual adverse eventInternational Journal of Dermatology, 2006
- New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonistsAnnals of the Rheumatic Diseases, 2006
- Psoriasis induced by anti–tumor necrosis factor therapy: A paradoxical adverse reactionArthritis & Rheumatism, 2005
- Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse modelJournal of Clinical Investigation, 2003
- Insights Into the Pathogenesis of Psoriasis and Psoriatic ArthritisThe American Journal of the Medical Sciences, 1998